Literature DB >> 18398594

[Diagnostic radiology of the pelvis. Prostate cancer, bladder cancer, and incontinence].

U G Mueller-Lisse M B A1.   

Abstract

Prostate cancer, bladder cancer, and pelvic floor weakness are among the most common diseases of the pelvis. Cardinal symptoms include painless macrohematuria in bladder cancer and urinary and fecal incontinence in pelvic floor weakness. Suspicion of prostate cancer currently is most frequently raised when the serum concentration of prostate-specific antigen is pathologically elevated. Besides extensive clinical and invasive diagnosis, clinical imaging is frequently applied for the localization, locoregional staging, and diagnosis of recurrence of prostate cancer and invasive bladder cancer, and in clinically difficult cases of cystocele, enterocele, rectocele, descensus or prolapse of vagina, uterus, and rectum, and rectal intussusception. Magnetic resonance imaging with T2-weighted TSE or FSE images in several planes combined with either axial, T1-weighted images and MR spectroscopy for the prostate, dynamic contrast-enhanced T1-weighted images for the urinary bladder, or dynamic T2-weighted functional images for pelvic floor incontinence are particularly well suited as clinical imaging methods.

Entities:  

Mesh:

Year:  2008        PMID: 18398594     DOI: 10.1007/s00117-008-1648-3

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  17 in total

Review 1.  Dynamic MR imaging of female organ prolapse.

Authors:  Harpreet K Pannu
Journal:  Radiol Clin North Am       Date:  2003-03       Impact factor: 2.303

Review 2.  New imaging modalities in bladder cancer.

Authors:  Mansi A Saksena; Douglas M Dahl; Mukesh G Harisinghani
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

3.  Dynamic MR colpocystorectography assessing pelvic-floor descent.

Authors:  A Lienemann; C Anthuber; A Baron; P Kohz; M Reiser
Journal:  Eur Radiol       Date:  1997       Impact factor: 5.315

Review 4.  Dynamic MR defecography of the posterior compartment: Indications, techniques and MRI features.

Authors:  Koenraad J Mortele; Janice Fairhurst
Journal:  Eur J Radiol       Date:  2006-12-04       Impact factor: 3.528

5.  Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging--clinicopathologic study.

Authors:  J Scheidler; H Hricak; D B Vigneron; K K Yu; D L Sokolov; L R Huang; C J Zaloudek; S J Nelson; P R Carroll; J Kurhanewicz
Journal:  Radiology       Date:  1999-11       Impact factor: 11.105

6.  Reliability of MR imaging-based virtual cystoscopy in the diagnosis of cancer of the urinary bladder.

Authors:  Markus Lämmle; Ambros Beer; Marcus Settles; Christian Hannig; Hartwig Schwaibold; Carsten Drews
Journal:  AJR Am J Roentgenol       Date:  2002-06       Impact factor: 3.959

7.  Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution.

Authors:  J Kurhanewicz; D B Vigneron; H Hricak; P Narayan; P Carroll; S J Nelson
Journal:  Radiology       Date:  1996-03       Impact factor: 11.105

Review 8.  Imaging prostate cancer: a multidisciplinary perspective.

Authors:  Hedvig Hricak; Peter L Choyke; Steven C Eberhardt; Steven A Leibel; Peter T Scardino
Journal:  Radiology       Date:  2007-04       Impact factor: 11.105

Review 9.  [Which are reasonable diagnostic procedures in the evaluation of urinary incontinence in the elderly?].

Authors:  C Hampel; R Gillitzer; C Wiesner; J W Thüroff
Journal:  Urologe A       Date:  2007-04       Impact factor: 0.639

Review 10.  [1H magnetic resonance spectroscopy of the prostate].

Authors:  U G Mueller-Lisse; M Scherr
Journal:  Radiologe       Date:  2003-06       Impact factor: 0.635

View more
  1 in total

1.  [Diagnose importance of multiparametric magnetic resonance tomography for prostate cancer].

Authors:  B J Fueger; T H Helbich; M Schernthaner; S Zbýn; H G Linhart; A Stiglbauer; A Doan; K Pinker; G Heinz; A R Padhani; P Brader
Journal:  Radiologe       Date:  2011-11       Impact factor: 0.635

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.